B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

Description: B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

Summary


The report provides comprehensive information on the therapeutics under development for B-Cell Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Non-Hodgkin Lymphoma and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma
- The report reviews pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved B-Cell Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses B-Cell Non-Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

Introduction

B-Cell Non-Hodgkin Lymphoma Overview

Therapeutics Development

B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies

B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes

B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance

B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies

B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes

B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development

B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment

Drug Profiles

B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates

B-Cell Non-Hodgkin Lymphoma - Dormant Projects

B-Cell Non-Hodgkin Lymphoma - Discontinued Products

B-Cell Non-Hodgkin Lymphoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2016

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Development by Companies, H1 2016 (Contd..6)

Number of Products under Development by Companies, H1 2016 (Contd..7)
Number of Products under Development by Companies, H1 2016 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Products under Development by Companies, H1 2016 (Contd..5)
Products under Development by Companies, H1 2016 (Contd..6)
Products under Development by Companies, H1 2016 (Contd..7)
Products under Development by Companies, H1 2016 (Contd..8)
Products under Development by Companies, H1 2016 (Contd..9)
Products under Development by Companies, H1 2016 (Contd..10)
Products under Development by Companies, H1 2016 (Contd..11)
Products under Development by Companies, H1 2016 (Contd..12)
Products under Development by Companies, H1 2016 (Contd..13)
Products under Development by Companies, H1 2016 (Contd..14)
Products under Development by Companies, H1 2016 (Contd..15)
Products under Development by Companies, H1 2016 (Contd..16)
Products under Development by Companies, H1 2016 (Contd..17)
Products under Development by Companies, H1 2016 (Contd..18)
Products under Development by Companies, H1 2016 (Contd..19)
Products under Development by Companies, H1 2016 (Contd..20)
Products under Development by Companies, H1 2016 (Contd..21)
Products under Development by Companies, H1 2016 (Contd..22)
Products under Development by Companies, H1 2016 (Contd..23)
Products under Development by Companies, H1 2016 (Contd..24)
Products under Development by Companies, H1 2016 (Contd..25)
Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)

B-Cell Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Acelylon Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Affimed Therapeutics Sarl, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Altos BioScience Corporation, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Arvinas, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by BeiGene, Ltd., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by BIND Therapeutics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Biocon Limited, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Biogenomics Limited, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Biothera, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Bluebird bio, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Cell>Point, L.L.C., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Curis, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co., Ltd., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Genosco, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunovaccine, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Limited, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by JHL Biotech, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Karus Therapeutics Limited, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Les Laboratoires Servier SAS, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by LFB S.A., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by mAbxience S.A., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Medivation, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by MEI Pharma, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Selvita S.A., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by United BioPharma, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics, Inc., H1 2016
B-Cell Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
B-Cell Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects, H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H1 2016
B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H1 2016
B-Cell Non-Hodgkin Lymphoma - Discontinued Products, H1 2016
B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H1 2016
B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H1 2016
B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H1 2016
B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H1 2016

List of Figures

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2016
Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3746950/](http://www.researchandmarkets.com/reports/3746950/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3746950/
Office Code: SCPLJFDX

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>✔</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>✔</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>✔</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof

First Name: __________________________  Last Name: __________________________

Email Address: * __________________________

Job Title: __________________________

Organisation: __________________________

Address: __________________________

City: __________________________

Postal / Zip Code: __________________________

Country: __________________________

Phone Number: __________________________

Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World